Abstract
Hemodiafiltration (HDF) seems to represent the gold standard in the field of replacement of renal function by dialysis. High convective fluxes have been correlated with better clinical outcomes. Sometimes, however, there are technical barriers to the achievement of high blood flows adequate to perform effective convective therapies. In spite of optimized procedures, the progressive increase in transmembrane pressure (TMP), the blood viscosity due to hemoconcentration and blood path resistance sometimes becomes inevitable. We propose two possible solutions that can be operated automatically via specific software in the dialysis machine: predilution on demand and backflush on demand. Predilution on demand consists in an automatic feedback of the machine, diverting part of the filtered dialysate into a predilution mode with an infusion of 200 ml in 30 s while the ultrafiltration pump stops. This produces a sudden hemodilution with a return of the parameters to acceptable values. The performance of the filter improves, and the pressure alterations are mitigated. Backflush on demand consists in an automatic feedback of the machine triggered by the TMP control, producing a positive pressure in the dialysate compartment due to a stop of filtration and rapid infusion of at least 100 ml of ultrapure dialysate into the hollow fiber. This not only produces a significant hemodilution, but also backflushes the membrane pores detaching protein layers and improving membrane permeability. These are two examples of how technology will permit to overcome technical barriers to a widespread diffusion of HDF and adequate convective dose delivery.
Journal Section:
Review
References
1.
Henderson LW: Biophysics of ultrafiltration and hemofiltration; in Maher JF (ed): Replacement of Renal Function by Dialysis. Dordrecht, Kluwer Academic, 1989, pp 300-326.
2.
Ledebo I: On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. J Am Soc Nephrol 2002;13(suppl 1):S78-S83.
[PubMed]
3.
Ronco C, Cruz D: Hemodiafiltration history, technology, and clinical results. Adv Chronic Kidney Dis 2007;14:231-243.
[PubMed]
4.
Ronco C, Heifetz A, Fox K, Curtin C, Brendolan A, Gastaldon F, et al: Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. Int J Artif Organs 1997;20:136-143.
[PubMed]
5.
Vienken J, Ronco C: New developments in hemodialyzers. Contrib Nephrol 2001;133:105-118.
[PubMed]
6.
Canaud B, Barbieri C, Marcelli D, Bellocchio F, Bowry S, Mari F, Amato C, Gatti E: Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int 2015, Epub ahead of print.
[PubMed]
7.
Lévesque R, Marcelli D, Cardinal H, Caron ML, Grooteman MP, Bots ML, Blankestijn PJ, Nubé MJ, Grassmann A, Canaud B, Gandjour A: Cost-effectiveness analysis of high-efficiency hemodiafiltration versus low-flux hemodialysis based on the Canadian arm of the CONTRAST study. Appl Health Econ Health Policy 2015, Epub ahead of print.
[PubMed]
8.
Kim JC, Garzotto F, Cruz DN, Goh CY, Nalesso F, Kim JH, Kang E, Kim HC, Ronco C: Enhancement of solute removal in a hollow-fiber hemodialyzer by mechanical vibration. Blood Purif 2011;31:227-234.
[PubMed]
9.
Kim JC, Kim JH, Sung J, Kim HC, Kang E, Lee SH, Kim JK, Kim HC, Min BG, Ronco C: Effects of arterial port design on blood flow distribution in hemodialyzers. Blood Purif 2009;28:260-267.
[PubMed]
10.
Kim JC, Kim JH, Kim HC, Kang E, Kim KG, Kim HC, Min BG, Ronco C: Effect of fiber structure on dialysate flow profile and hollow-fiber hemodialyzer reliability: CT perfusion study. Int J Artif Organs 2008;31:944-950.
[PubMed]
11.
Martín-Malo A, Aljama P: On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006;17:2315-2321.
[PubMed]
12.
Henderson LW, Beans E: Successful production of sterile pyrogen-free electrolyte solution by ultrafiltration. Kidney Int 1978;14:522-525.
[PubMed]
13.
Henderson LW, Sanfelippo ML, Beans E: ‘On line' preparation of sterile pyrogen-free electrolyte solution. Trans Am Soc Artif Intern Organs 1978;24:465-467.
[PubMed]
14.
Canaud B: Online hemodiafiltration. Technical options and best clinical practices. Contrib Nephrol 2007;158:110-122.
[PubMed]
15.
Roy T: Technical and microbiological safety of online hemodiafiltration: a European perspective. Semin Dialysis 1999;12:S81-S87.
16.
Canaud B, Mion C: Water treatment for contemporary hemodialysis; in Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds): Replacement of Renal Function by Dialysis, ed 4. Dordrecht, Kluwer Academic Publishers, 1996, vol 8, pp 232-255.
17.
Canaud B, Bosc JY, Leblanc M, Garred LJ, Vo T, Mion C: Evaluation of high-flux hemodiafiltration efficiency using an on-line urea monitor. Am J Kidney Dis 1998;31:74-80.
[PubMed]
18.
Shinzato T, Kobayakawa H, Maeda K: Comparison of various treatment modes in terms of beta 2-microglobulin removal: hemodialysis, hemofiltration, and push/pull HDF. Artif Organs 1989;13:66-70.
[PubMed]
19.
Vanholder R, Meert N, Schepers E, Glorieux G: From uremic toxin retention to removal by convection: do we know enough? Contrib Nephrol 2008;161:125-131.
[PubMed]
20.
Santoro A, Ferramosca E, Mancini E, Monari C, Varasani M, Sereni L, Wratten M: Reverse mid-dilution: new way to remove small and middle molecules as well as phosphate with high intrafilter convective clearance. Nephrol Dial Transplant 2007;22:2000-2005.
[PubMed]
21.
Lornoy W, De Meester J, Becaus I, Billiouw JM, Van Malderen PA, Van Pottelberge M: Impact of convective flow on phosphorus removal in maintenance hemodialysis patients. J Ren Nutr 2006;16:47-53.
[PubMed]
22.
Zehnder C, Gutzwiller JP, Renggli K: Hemodiafiltration: a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999;52:152.
[PubMed]
23.
Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Lévesque R, Nubé MJ, Bots ML, Blankestijn PJ, ter Wee PM; CONTRAST Investigators: Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 2010;55:77-87.
[PubMed]
24.
Davenport A, Gardner C, Delaney M; Pan Thames Renal Audit Group: The effect of dialysis modality on phosphate control: haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010;25:897-901.
[PubMed]
25.
Lornoy W, Becaus I, Billiouw JM, et al: On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant 2000;15(suppl 1):49.
[PubMed]
26.
Maduell F, del Pozo C, Garcia H, et al: Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999;14:1202.
[PubMed]
27.
Padrini R, Canova C, Conz P, Mancini E, Rizzioli E, Santoro A: Convective and adsorptive removal of beta2-microglobulin during predilutional and postdilutional hemofiltration. Kidney Int 2005;68:2331-2337.
[PubMed]
28.
Locatelli F, Mastrangelo F, Redaelli B, et al: Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996;50:1293.
[PubMed]
29.
Susantitaphong P, Tiranathanagul K, Katavetin P, Townamchai N, Praditpornsilpa K, Tungsanga K, Eiam-Ong S: Efficacy of convective-controlled double high-flux hemodiafiltration versus on-line hemodiafiltration: 1-year prospective study. Blood Purif 2010;29:35-43.
[PubMed]
30.
Mandolfo S, Borlandelli S, Imbasciati E: Leptin and beta2-microglobulin kinetics with three different dialysis modalities. Int J Artif Organs 2006;29:949-955.
[PubMed]
31.
Widjaja A, Kielstein JT, Horn R, et al: Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant 2000;15:846.
[PubMed]
32.
Kim S, Oh KH, Chin HJ, Na KY, Kim YS, Chae DW, Ahn C, Han JS, Kim S, Joo KW: Effective removal of leptin via hemodiafiltration with on-line endogenous reinfusion therapy. Clin Nephrol 2009;72:442-448.
[PubMed]
33.
Tetta C, Bellomo R, D'Intini V, et al: Do circulating cytokines really matter in sepsis? Kidney Int Suppl 2003;84:S69.
[PubMed]
34.
Van Tellingen A, Grooteman MP, Schoorl M, et al: Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002;62:632.
[PubMed]
35.
Canaud B, Wizemann V, Pizzarelli F, et al: Cellular interleukin-1 receptor antagonist production in patients receiving on-line haemodiafiltration therapy. Nephrol Dial Transplant 2001;16:2181.
[PubMed]
36.
Carracedo J, Merino A, Nogueras S, Carretero D, Berdud I, Ramírez R, Tetta C, Rodríguez M, Martín-Malo A, Aljama P: On-line hemodiafiltration reduces the proinflammatory CD14+CD16+ monocyte-derived dendritic cells: a prospective, crossover study. J Am Soc Nephrol 2006;17:2315-2321.
[PubMed]
37.
Stein G, Franke S, Mahiout A, et al: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999.
[PubMed]
38.
Niwa T, Asada H, Tsutsui S, et al: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol 1995;15:463.
[PubMed]
39.
Kawano Y, Takaue Y, Kuroda Y, et al: Effect of alleviation of renal anemia by hemodialysis using the high flux dialyzer BK-F. Kidney Dial 1994;34:200-203.
40.
Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, Evenepoel P: The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009;54:891-901.
[PubMed]
41.
Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:278-285.
[PubMed]
42.
Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, Wanner C, Canaud B: Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 2010;25:212-218.
[PubMed]
43.
Altieri P, Sorba G, Bolasco P, Asproni E, Ledebo I, Cossu M, Ferrara R, Ganadu M, Cadinu F, Serra G, Cabiddu G, Sau G, Casu D, Passaghe M, Bolasco F, Pistis R, Ghisu T; Second Sardinian Multicentre Study: Predilution haemofiltration - the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study. Nephrol Dial Transplant 2001;16:1207-1213.
[PubMed]
44.
Mion M, Kerr PG, Argiles A, Canaud B, Flavier JL, Mion CM: Haemodiafiltration in high-cardiovascular-risk patients. Nephrol Dial Transplant 1992;7:453-454.
[PubMed]
45.
Tiranathanagul K, Praditpornsilpa K, Katavetin P, Srisawat N, Townamchai N, Susantitaphong P, Tungsanga K, Eiam-Ong S: On-line hemodiafiltration in Southeast Asia: a three-year prospective study of a single center. Ther Apher Dial 2009;13:56-62.
[PubMed]
46.
McKane W, Chandna SM, Tattersall JE, et al: Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002;61:256.
[PubMed]
47.
Locatelli F, Del Vecchio L: Dialysis adequacy and response to erythropoietic agents: what is the evidence base? Nephrol Dial Transplant 2003;18(suppl 8):viii29-viii35.
[PubMed]
48.
Vaslaki L, Major L, Berta K, Karatson A, Misz M, Pethoe F, Ladanyi E, Fodor B, Stein G, Pischetsrieder M, Zima T, Wojke R, Gauly A, Passlick-Deetjen J: On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006;24:163-173.
[PubMed]
49.
Muñoz R, Gallardo I, Valladares E, Saracho R, Martínez I, Ocharan J, Montenegro J: Online hemodiafiltration: 4 years of clinical experience. Hemodial Int 2006;10(suppl 1):S28-S32.
[PubMed]
50.
Fischbach M, Dheu C, Seuge L, Orfanos N: Hemodialysis and nutritional status in children: malnutrition and cachexia. J Ren Nutr 2009;19:91-94.
[PubMed]
51.
Fischbach M, Terzic J, Menouer S, Dheu C, Seuge L, Zalosczic A: Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis. Nephrol Dial Transplant 2010;25:867-873.
[PubMed]
52.
Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillepsie BW, Depner T, Klassen P, Port F: Patients receiving hemodiafiltration or hemofiltration have lower mortality risk than patients receiving hemodialysis without replacement fluid in Europe: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2004;14:31A.
53.
Jirka T, Cesare S, Di Benedetto A, Perera Chang M, Ponce P, Richards N, Tetta C, Vaslaky L: Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int 2006;70:1524.
[PubMed]
54.
Vilar E, Fry AC, Wellsted D, Tattersall JE, Greenwood RN, Farrington K:. Long-term outcomes in online hemodiafiltration and high-flux hemodialysis: a comparative analysis. Clin J Am Soc Nephrol 2009;4:1944-1953.
[PubMed]
55.
Ok E, Gulay G, Sevinc Ok E, Kircelli F, Yilmaz M, Hur E, Demirci S, Ozdogan O, Demirci C, Sertoz O, Duman S, Ozkahya M, Kayikcioglu M, Elbi H, Basci A, Toz H: Comparison of postdilution on-line hemodiafiltration and hemodialysis. ERA-EDTA Congr, Prague, 2011, LBCT2.
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
